Notice NOT-HL-22-044 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-126 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-035 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) aims to support complementary research programs that adopt innovative scalable technologies to inventory, register and profile cellular ensembles and/or cell-types that produce and/or respond to opioids in the brain, or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches capable of integrating data generated through molecular profiling of brain tissues at single-cell resolution with other data modalities , such as neurophysiological activity, connectivity and/or spatial localization, collected from the same cells. The overarching goal of the FOA is to generate and disseminate multimodal reference datasets that will be useful to the research community and will provide a foundational biological framework to advance the understanding of opioid-associated states.

Notice NOT-CA-22-128 from the NIH Guide for Grants and Contracts

Notice NOT-HD-22-043 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-211 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-22-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the development, implementation, and maintenance of the AnVIL Clinical Resource (ACR), a suite of genomic-based clinical tools and services built into the NHGRI Data Science Analysis, Visualization, and Informatics Lab-Space (AnVIL) to foster clinical genomic research. AnVIL is a scalable and interoperable resource for the basic and clinical genomic research communities that leverages a cloud-based infrastructure to democratize data access, sharing, and computing across large genomic and genomic-related datasets.

Funding Opportunity RFA-NR-23-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to accelerate implementation of effective non-opioid interventions for chronic pain management in rural and remote populations. Projects include pragmatic, implementation, or hybrid effectiveness-implementation trials to improve pain management and reduce the use of inappropriate opioid medications. Awards made under this FOA will initially support a milestone-driven, planning phase (UG3) of 1 to 2 years, with possible transition to an implementation phase (UH3) of up to 4 years duration (5 years total for the two phases). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to support the "real world" implementation of effective interventions to manage pain in rural and remote areas. Results from the trials supported by this funding opportunity announcement (FOA) should inform policy makers, payers, community stakeholders, as well as health care providers and patients in the primary care, emergency department, hospital, home health, or dental setting. This FOA requires that the investigators partner with one or more rural healthcare system(s) to plan and implement the intervention. During the planning phase, investigators must develop an additional one or more community-based partnership(s). Studies may propose to integrate multi-component, bundled, or multi-level interventions that have demonstrated efficacy.

Funding Opportunity PAR-22-254 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide opportunities for eligible U.S. small business concerns (SBCs), together with academic partners, in the Northeast region of the Institutional Development Award (IDeA)-eligible states, to apply forIDeA Regional Entrepreneurship Development (I-RED) program awards that support the development of educational products to promote biomedical entrepreneurship in the Northeast region of IDeA states. These educational products are expected to address the needs of IDeA state academic institutions in developing and/or strengthening technology transfer programs that stimulate technological innovation by translating scientific discoveries and technologies from research laboratories into commercial products that improve human health and promote economic growth in the Northeast region of IDeA states.

Notice NOT-OD-22-210 from the NIH Guide for Grants and Contracts

Notice NOT-EY-22-016 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-23-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

Funding Opportunity RFA-NS-23-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

Notice NOT-AG-22-037 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-024 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-22-036 from the NIH Guide for Grants and Contracts. The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOAs (RFA-CA-22-035).

Funding Opportunity RFA-CA-22-035 from the NIH Guide for Grants and Contracts. The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOAs (RFA-CA-22-036 or RFA-CA-22-037).

Funding Opportunity RFA-CA-22-037 from the NIH Guide for Grants and Contracts. The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-22-035). This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena

Funding Opportunity PAR-22-250 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for NIH individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH. The goal of this FOA is to support existing COBRE Phase 1 Centers by further strengthening the research infrastructure and to continue the development and support of a critical mass of investigators with the expertise in the Center's scientific interest areas.

Notice NOT-HS-22-023 from the NIH Guide for Grants and Contracts